E411(A) Open for men and non childbearing women

Gender: Male and Female

Smoking habit: Non / Ex-smoker only

Age: 18 - 55 years old

Up to $ 3,000

BMI : 18.00 - 32.00

Food restrictions : Fast

Clinic stay

  • 14 Jun (12:00 pm) to 16 Jun (8:00 am)
  • 19 Jun (12:00 pm) to 28 Jun (8:00 am)

Return visits

  • 17 Jun (8:00 am)
  • 18 Jun (8:00 am)
  • 19 Jun (8:00 am)
  • 29 Jun (8:00 am)
  • 30 Jun (8:00 am)
  • 1 Jul (8:00 am)

Medication type

Lonafarnib is being developed to treat chronic hepatitis D virus (HDV) infection.
Dose: 50 mg lonafarnib
Ritonavir is FDA approved to treat human immunodeficiency virus (HIV). It is being used in this study as a “booster” to increase the concentration of lonafarnib in your body. A “booster” is a drug that keeps your body from breaking down a drug before it works.
Dose: 100 mg ritonavir

Notes

This drug indicated in the treatment of chronic HDV infection.
Women must be of non-childbearing potential.

This is preliminary information and changes could occur without notice